Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans Purchases 5,000 Shares

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) CFO Daron Evans bought 5,000 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was acquired at an average price of $4.05 per share, for a total transaction of $20,250.00. Following the acquisition, the chief financial officer now directly owns 268,900 shares in the company, valued at $1,089,045. The trade was a 1.89% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Daron Evans also recently made the following trade(s):

• On Wednesday, March 26th, Daron Evans bought 10,000 shares of Rezolute stock. The stock was acquired at an average price of $2.89 per share, for a total transaction of $28,900.00.

Rezolute Stock Performance

NASDAQ:RZLT traded up $0.09 on Wednesday, hitting $4.33. The stock had a trading volume of 795,031 shares, compared to its average volume of 586,373. The stock has a market cap of $370.30 million, a P/E ratio of -3.77 and a beta of 1.04. Rezolute, Inc. has a 1 year low of $2.22 and a 1 year high of $6.19. The firm's fifty day simple moving average is $3.92 and its two-hundred day simple moving average is $4.09.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Equities research analysts predict that Rezolute, Inc. will post -0.93 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RZLT. Charles Schwab Investment Management Inc. grew its position in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after acquiring an additional 9,000 shares during the period. American Century Companies Inc. grew its position in shares of Rezolute by 62.1% during the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after acquiring an additional 24,742 shares during the period. Geode Capital Management LLC grew its position in shares of Rezolute by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after acquiring an additional 25,413 shares during the period. ExodusPoint Capital Management LP bought a new position in shares of Rezolute during the 4th quarter valued at approximately $277,000. Finally, Barclays PLC bought a new position in shares of Rezolute during the 4th quarter valued at approximately $314,000. 82.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RZLT. Wedbush restated an "outperform" rating and issued a $12.00 target price on shares of Rezolute in a report on Wednesday, May 14th. Wall Street Zen lowered shares of Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Rezolute currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.83.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.